Latest
- Report
Follow-Up About the Budgetary Treatment of Cost-Sharing Reductions
CBO provides additional information to Congressman Mark Meadows about the budgetary treatment of the government’s payments to reimburse health care insurers for cost-sharing reductions they provide to eligible people.
- Report
CBO’s Estimates of the Effects of Changes in the Manufacturers’ Discount in the Part D Coverage Gap
In a letter to Congressman Mark Meadows, CBO explains its estimate for section 53116 of the Bipartisan Budget Act requiring brand-name prescription drug manufacturers to increase the discount offered to some Medicare Part D beneficiaries.
- Cost Estimate
S. 2837, Preventing Drug Diversion Act of 2018
As reported by the Senate Committee on the Judiciary on June 19, 2018
- Cost Estimate
S. 2680, Opioid Crisis Response Act of 2018
As reported by the Senate Committee on Health, Education, Labor, and Pensions on May 7, 2018
- Cost Estimate
S. 2645, Access to Increased Drug Disposal Act of 2018
As reported by the Senate Committee on the Judiciary on June 19, 2018
- Cost Estimate
H.R. 4952, Improving Seniors Access to Quality Benefits Act
As ordered reported by the House Committee on Ways and Means on June 21, 2018
- Presentation
CBO’s Analyses and Projections of Federal Health Care Costs
Presentation by Robert Sunshine, Senior Advisor in CBO’s Office of the Director, at the 10th Annual Meeting of the OECD Network of Parliamentary Budget Officials and Independent Fiscal Institutions.
- Cost Estimate
H.R. 5762, Joint Task Force to Combat Opioid Trafficking Act of 2018
As passed by the House of Representatives on June 19, 2018.
- Cost Estimate
S. 2535, Opioid Quota Reform Act
As reported by the Senate Committee on the Judiciary on June 19, 2018.
- Cost Estimate
S. 207, Synthetic Abuse and Labeling of Toxic Substances Act of 2017
As reported by the Senate Committee on the Judiciary on June 19, 2018.